Exchange: NYSEMkt·Updated 07:34 PM EDT
News
all
press releases
Profound Medical (PROF) Q2 Earnings Surpass Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +218.18% and -55.66%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Zacks
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Zacks
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Zacks
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued...
PR Newswire
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors PR Newswire VANCOUVER, BC, Jan. 30, 2026 Issued on behalf of...
PR Newswire
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rigel Pharmaceuticals (RIGL) Tops Q3 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +56.99% and +12.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.